Renaissance Technologies - NAVIDEA BIOPHARMACEUTICALS I ownership

NAVIDEA BIOPHARMACEUTICALS I's ticker is NAVB and the CUSIP is 63937X202. A total of 40 filers reported holding NAVIDEA BIOPHARMACEUTICALS I in Q3 2020. The put-call ratio across all filers is 0.51 and the average weighting 0.0%.

Quarter-by-quarter ownership
Renaissance Technologies ownership history of NAVIDEA BIOPHARMACEUTICALS I
ValueSharesWeighting
Q1 2023$62
+342.9%
238,133
+264.5%
0.00%
Q4 2022$14
-99.8%
65,333
+152.9%
0.00%
Q3 2022$7,000
-22.2%
25,833
+104.5%
0.00%
Q2 2022$9,000
-96.6%
12,633
-90.4%
0.00%
Q1 2021$266,000
+121.7%
131,618
+136.3%
0.00%
Q4 2020$120,000
-53.8%
55,695
-42.1%
0.00%
Q3 2020$260,000
-73.5%
96,148
-61.4%
0.00%
-100.0%
Q2 2020$981,000249,0000.00%
Other shareholders
NAVIDEA BIOPHARMACEUTICALS I shareholders Q3 2020
NameSharesValueWeighting ↓
Allred Capital Management, LLC 52,926$113,0000.06%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 109,940$236,0000.01%
PATHSTONE FAMILY OFFICE, LLC 10,050$22,0000.00%
Sowell Financial Services LLC 11,190$24,0000.00%
TWO SIGMA INVESTMENTS, LP 101,949$219,0000.00%
SUSQUEHANNA FUNDAMENTAL INVESTMENTS, LLC 32,822$71,0000.00%
UBS Group AG 816$2,0000.00%
IFP Advisors, Inc 50$00.00%
OSAIC HOLDINGS, INC. 6$00.00%
Jacobi Capital Management LLC 1,000$2,0000.00%
View complete list of NAVIDEA BIOPHARMACEUTICALS I shareholders